Venous Thromboembolism

Patients hospitalized for HF were found to have significantly elevated long-term risk for venous thromboembolism, regardless of ejection fraction.

Researchers found that using an intestinal ultrasound to assess bowel wall thickness can help monitor treatment response in patients with ulcerative colitis. This was one of the top stories in gastroenterology last week.

Frequent and early onset of venous thromboembolism are associated with decreased progression-free survival and overall survival among patients diagnosed with pancreatic ductal adenocarcinoma, according to study results.

Black patients with cancer appeared to be at a higher risk for cancer-associated venous thromboembolism than patients of other races, according to results of a retrospective study published in American Journal of Clinical Oncology.

ORLANDO — A 3-week treatment cycle of efgartigimod, a neonatal Fc receptor antagonist, was well tolerated and effective in patients with primary immune thrombocytopenia, according to phase 2 data presented at the ASH Annual Meeting and Exposition.

ORLANDO — Apixaban reduced the risk for recurrent venous thromboembolism compared with low-molecular-weight heparin and warfarin, according to results of a large epidemiology study presented at the ASH Annual Meeting and Exposition.

There was no difference in venous thromboembolism and wound drainage rates in a comparison of chemoprophylactic agents used in low-risk patients who underwent revision compared with primary total joint arthroplasty, according to study results.

ORLANDO — In this video at the ASH Annual Meeting and Exposition, Thein H. Oo, MD, FRCPE, FACP, reviews a study that showed the addition of aspirin to direct oral anticoagulants for venous thromboembolism or non-valvular atrial fibrillation was linked to an increase in bleeding events.

ORLANDO — Tranexamic acid is an efficacious and economical strategy to reduce bleeding among patients who undergo total joint arthroplasty, a presenter at the Current Concepts in Joint Replacement Winter Meeting said, here.

ORLANDO — Body weight-adjusted regimens of rivaroxaban appeared to be safe and effective for children with venous thromboembolism, according to results of a dose-exposure-response evaluation of the phase 3 EINSTEIN-Jr. study presented at ASH Annual Meeting and Exposition.